[The expectations for results of clinical trial "IDEAL"].

The current standard therapy in terms of treatment efficacy is the combination of peginterferon and ribavirin. Many factors affects response to this therapy: viral factors, host factors, factors related to therapy. The overall sustained virological response (SVR) is only 50%-61% among patients infected with genotype 1,4, following 48 weeks therapy and 78%-88% among patients infected with genotype 2,3, following 24 weeks therapy. Because there are some differences between the two brands of peginterferon clinicians are awaiting more information regarding the most effective anti-viral schedule for naive patients with chronic hepatitis C, particulary with genotype 1,4. IDEAL is the current ongoing trial comparing the effectiveness of these two form peginterferons approved for the treatment of chronic hepatitis C.